DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutations in the photoreceptor-specific flippase ABCA4 are associated with Stargardt disease and many other forms of retinal degeneration that currently lack curative therapies. Gene replacement is a logical strategy for ABCA4-associated disease, particularly given the current success of traditional viral-mediated gene delivery, such as with adeno-associated viral (AAV) vectors. However, the large size of the ABCA4 cDNA (6.8 kbp) has hampered progress in the development of genetic treatments. Nonviral DNA nanoparticles (NPs) can accommodate large genes, unlike traditional viral vectors, which have capacity limitations. We utilized an optimized DNA NP technology to subretinally deliver ABCA4 to Abca4-deficient mice. We detected persistent ABCA4 transgene expression for up to 8 months after injection and found marked correction of functional and structural Stargardt phenotypes, such as improved recovery of dark adaptation and reduced lipofuscin granules. These data suggest that DNA NPs may be an excellent, clinically relevant gene delivery approach for genes too large for traditional viral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Outstanding studies from Naash and colleagues showed that rod-shaped CK30-PEG (polyethylene glycol)-compacted NPs effectively transfected both RPE and photoreceptors and showed efficacious gene therapy of Rpe65−/− (retinal pigment epithelium 65; model of LCA) and Abca4−/− (Stargardt Disease) mice [39,40,41].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Generally, these methods carry low risk of immune responses commonly associated with viral delivery [44,63,64].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Single-molecule DNA nanoparticles compacted by polyethylene glycol (PEG)-substituted lysine peptides (CK30-PEG) have been used to carry payloads up to 20 kb in size,82,83 with several groups demonstrating their safety in BALB/c mice and rds+/− Rho-/- or Abca4-/- mouse models of retinal degeneration.82–86”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 1×
“Given the packaging capacity of our NPs, we evaluated whether they could express the large ABCA4 therapeutic gene and mediate improvement in a Stargardt disease model (15).”
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. H., Kowalczyk, T. H., Hyatt, S. L., Fink, T. L., Gedeon, C. R., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1255 · Cited by 298
Self-citationAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“(12); however, subsequent reports demonstrated that the AAVs employed contained a heterogenous mix of DNA, not intact ABCA4 expression cassettes (13).”
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Biochemical defects in ABCR protein variants associated with human retinopathies
Sun, H., Smallwood, P. M., & Nathans, J. (2000) · Nature Genetics · doi:10.1038/79994 · Cited by 203
Nanoparticles of Compacted DNA Transfect Postmitotic Cells
Liu, G., Li, D., Pasumarthy, M. K., Kowalczyk, T. H., Gedeon, C. R., Hyatt, S. L., Payne, J. M., Miller, T. J., Brunovskis, P., Fink, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305776200 · Cited by 190
Self-citationTransfection of airway epithelium by stable PEGylated poly-l-lysine DNA nanoparticles in vivo
Ziady, A.-G., Gedeon, C. R., Miller, T., Quan, W., Payne, J. M., Hyatt, S. L., Fink, T. L., Muhammad, O., Oette, S., Kowalczyk, T., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.07.007 · Cited by 165
Self-citationFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“Studies using luciferase reporter vectors ranging in size from 5.3 to 20.2 kbp (generated by introducing λ -bacteriophage DNA fragments into the parent plasmid) demonstrated comparable gene expression regardless of vector size, suggesting that these NPs could deliver large genes (10).”
InfluentialSelf-citationCai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2010) · The FASEB Journal · doi:10.1096/fj.09-139147 · Cited by 120
Self-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 3×
“They have recently been used to mediate phenotypic rescue in rodent models of retinitis pig-mentosa, Parkinson disease, and cystic fibrosis, and were safely employed in a phase I/II clinical trial for cystic fibrosis (2, 8, 9).”
Self-citation
Research works printed but not linked: 1
- Glushakova, 2006, Mol Vis., 12, 298
Cited by
Items 101–150 of 150
Zheng, M., Mitra, R. N., Weiss, E. R., & Han, Z. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.031 · Cited by 14
Self-citationGene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 15
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Simna, S. P., & Han, Z. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210419090357 · Cited by 11
Self-citationRecent developments in regenerative ophthalmology
Shen, Y., Shen, H., Guo, D., Sun, X., Sun, Y., Hong, N., Wang, X., Xie, C., Zhao, Y., He, Q., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1684-x · Cited by 13
Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases
Wang, Y., Rajala, A., & Rajala, R. V. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_15 · Cited by 12
Nanotherapy for Neural Retinal Regeneration
Yu, C., Dong, L., Lv, Y., Shi, X., Zhang, R., Zhou, W., Wu, H., Li, H., Li, Y., Zhou, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202409854 · Cited by 13
Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 12
Eblimit, A., Makia, M. S., Strayve, D., Crane, R., Conley, S. M., Sinha, T., Acharya, G. S., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091510 · Cited by 8
Self-citationEffective intravitreal gene delivery to retinal pigment epithelium with hyaluronic acid nanospheres
Crane, R., Makia, M. S., Zeibak, S., Tebbe, L., Ikelle, L., Woods, C. R., Conley, S. M., Acharya, G. S., Naash, M. I., & Al‐Ubaidi, M. R. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102222 · Cited by 9
Self-citationRecent Advances in Smart Polymers-Based Therapeutics in Ophthalmology
Xie, J., Nie, L., & Pei, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s530124 · Cited by 11
Peynshaert, K., Devoldere, J., Smedt, S. C. D., & Remaut, K. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2167979 · Cited by 7
Simna, S. P., Mitra, R. N., Zheng, M., Chrispell, J. D., Wang, K., Kwon, Y., Weiss, E. R., & Han, Z. (2023) · Gene Therapy · doi:10.1038/s41434-023-00394-1 · Cited by 7
Self-citationCattaneo, A. G., Gornati, R., Bernardini, G., Sabbioni, E., Manzo, L., & Gioacchino, M. D. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch13 · Cited by 5
Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
Gemayel, M. C., Byrne, L. C., Ciulla, T. A., & Sahel, J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000360 · Cited by 5
DNA- and RNA-based Gene Therapies in Ophthalmology
Ciulla, T. A., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000359 · Cited by 4
Genes and Gene Therapy in Inherited Retinal Disease
Shughoury, A., Ciulla, T. A., Bakall, B., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000377 · Cited by 4
Application Prospects for Synthetic Nanoparticles in Optogenetic Retinal Prosthetics
Rotov, A. Y., Romanov, I. S., Tarakanchikova, Y. V., & Astakhova, L. A. (2021) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093021060132 · Cited by 4
Exploration: Nanoparticles in the Diagnosis and Treatment of Retinal Diseases
Wang, L., Xie, W., Chen, J., Zhao, L., Wen, Y., Xie, H., Shu, Q., Pan, F., Lu, J., Liu, Y., et al. (2023) · Journal of Nanomaterials · doi:10.1155/2023/9099778 · Cited by 4
Gene Therapy Using Genomic DNA
Han, Z. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00003-x · Cited by 4
Self-citationSobolewska, M., Świerczyńska, M., Dorecka, M., Wyględowska‐Promieńska, D., Krawczynski, M. R., & Mrukwa–Kominek, E. (2023) · Medicina · doi:10.3390/medicina59020399 · Cited by 3
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Challenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
Gene therapy for inherited retinal diseases
Dhooge, P. P. A., Valkenburg, D., & Hoyng, C. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00017-4 · Cited by 5
Georgiou, M., & Michaelides, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_2 · Cited by 4
Chakraborty, D., Conley, S. M., & Naash, M. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063321 · Cited by 2
Self-citationStargardt Disease: Gene Therapy Strategies for ABCA4
Ku, C. A., & Yang, P. G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000375 · Cited by 2
Stargardt disease: progress, enigmas, and prospects for therapeutic intervention
Palmgren, V. A. C., Pindwarawala, M., Hosseinzadeh, A., & Molday, R. S. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2645188 · Cited by 1
Nonviral Delivery Systems for Gene Therapy for Retina and Posterior Segment Disease
del Pozo‐Rodríguez, A., Torrecilla, J., Rodríguez‐Gascón, A., & Solinís, M. Á. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_8 · Cited by 2
Rajala, R. V. S. (2019) · PubMed · Cited by 1
Stieger, K., & Lorenz, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-28384-1_15 · Cited by 2
Camp, D. A., Gemayel, M. C., & Ciulla, T. A. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1898373 · Cited by 1
Pediatric genetic macular and choroidal diseases
Bergman, M. Y., & Nallasamy, S. (2015) · Journal of Pediatric Genetics · doi:10.3233/pge-14106
Expanding AAV cargo capacity for gene therapy of Stargardt disease
Trapani, I. (2014)
Manifestaciones clínicas en 4 casos con enfermedad de Stargardt
Sambricio, J., Suárez-Baraza, J., Campos-Pavón, J., de-Lucas-Viejo, B., del Fresno-Valencia, E., & Redondo-García, I. (2015) · Revista Mexicana de Oftalmología · doi:10.1016/j.mexoft.2015.08.003
Macular Dystrophies: Management and Interventions
Marazova, K., & Sahel, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-26621-3_11
Development of Helper-Dependent Adenoviral Vectors for Gene Therapy for Inherited Retinal Diseases
Lam, S. (2015) · TSpace (University of Toronto)
Optogenetics in Treating Retinal Disease
Nelidova, D., & Esposti, F. (2017) · Cambridge University Press eBooks · doi:10.1017/9781107281875.024
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7 · Cited by 1
Stargardt disease – what general ophthalmologists should know about this macular dystrophy
Lubiński, W., & Lachowicz, E. (2020) · Klinika Oczna · doi:10.5114/ko.2020.97546
Georgiou, M., & Michaelides, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_2-1 · Cited by 1
Karamichos, D. (2016) · MDPI eBooks · doi:10.3390/books978-3-03842-202-0
Stieger, K., & Lorenz, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-35055-9_15
Novel compound heterozygous CNGA3 mutation associated with retinal cone dystrophy
Sun, R., Wang, Y., Zhou, W., Chen, S., Li, Y., Pan, M., Ji, D., Li, J., & Shi, X. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12905 · Cited by 1
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
Goyal, S., & Vanita, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00042-4
Laich, Y., Georgiou, M., & Michaelides, M. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00009-4
Update on the Management of ABCA4 Retinopathy (Stargardt Disease)
Parameswarappa, D. C., Ratra, D., Chattannavar, G., & Padhy, S. K. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01407-z
Brovin, A. N., Sabantsev, M. O., Ignatieva, E. V., Baibarin, K. А., & Karabelsky, A. V. (2026) · Ophthalmology in Russia · doi:10.18008/1816-5095-2026-3-512-520
Metadata
- Authors
- Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- University of Oklahoma (US)
- Copernicus Therapeutics (United States) (US)
- Corresponding author
- Naash, Muna I.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-09-04
- Volume
- 122
- Issue
- 9
- Pages
- 3221-3226
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3428101
- OpenAlex
- W2055017226
- Cited by
- 150
- References
- 19
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 18 · 2014: 15 · 2013: 15 · 2012: 1
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation Fighting Blindness
- University of Oklahoma
- National Institutes of Health
- University of Oklahoma Health Sciences Center
- National Eye Institute (R01EY018656, R01EY022778, R01EY010609)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- DNA nanoparticles, ABCA4, Stargardt disease, gene replacement therapy, non-viral gene delivery, subretinal injection, retinal degeneration, photoreceptors, lipofuscin granules, dark adaptation
- MeSH terms
- Analysis of Variance, Animals, Corneal Dystrophies, Hereditary, DNA, Humans, Lipofuscin, Mice, Inbred C57BL, Phenotype, Genetic Therapy, Gene Expression, Mice, Knockout, ATP-Binding Cassette Transporters, Transgenes, Mice, Nanoparticles, Retinal Pigment Epithelium, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.